The immunoglobulin free light chain (FLC) is the precursor protein of amyloid in primary systemic amyloidosis (AL). Historically, the ability to monitor the amyloid protein precursor protein has been crude. We evaluated the utility of the FLC assay in a retrospective analysis of patients with AL undergoing peripheral blood stem cell transplant (PBSCT). Ninety-three such patients had serial FLC measurements (Freelite™) performed. The prognostic effects of the initial concentration and the extent of reduction of monoclonal FLC on survival were studied. There was a significantly higher risk of death in patients with higher baseline FLC (hazard ratio 2.6, p<0.04). Baseline FLC correlated with serum cardiac troponin levels, and higher FLC levels were associated with more organs involved by amyloid, suggesting that high FLC levels may be associated with more advanced disease. The percent FLC reduction did not predict for survival, but the absolute level of FLC achieved after therapy did. Normalization of FLC level post-PBSCT predicted for both organ response and complete hematologic response. Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio.
Introduction
The immunoglobulin free light chain (FLC) is the protein precursor of the amyloid formed in primary systemic amyloidosis (AL), 1, 2 and recent literature suggests that the amyloidogenic FLC may be directly toxic in patients with AL. 3 The present paradigm of therapy of AL is eradication of clonal bone marrow plasma cells in order to reduce or eliminate the circulating precursor protein. [4] [5] [6] [7] Until the advent of the FLC assay (Freelite™, The Binding Site Limited, Birmingham, U.K.), serial quantitation of the amyloid protein precursor has been crude, relying on the quantity of the intact serum monoclonal immunoglobulin, the amount of urine light chain, and the degree of bone marrow plasmacytosis. 5 The Freelite™ assay utilizes antibodies directed against FLC epitopes that are hidden in the process of light chains binding to immunoglobulin heavy chains, and has a sensitivity of < 0.5 mg/L. This compares with typical detection limits of 150-500 mg/L by immunofixation and 500-2000 mg/L by electrophoresis. 8, 9 Not only is the Freelite™ assay more sensitive than conventional measures, but also provides a tool to quantitate circulating FLC in patients with AL. [9] [10] [11] Quantitation of monoclonal proteins has required protein electrophoresis, and only approximately 25% of AL patients have "measurable" disease as defined by a serum protein electrophoresis M spike of 10 g/L. 11, 12 In contrast, with the
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Freelite™ assay, more than half of AL patients have "measurable disease" (i.e. a FLC of greater than 100 mg/L). [9] [10] [11] [12] Patients who achieve hematologic response by electrophoresis, immunofixation and bone marrow biopsy, have higher organ response rates and longer survival. [4] [5] [6] [7] 13 The measurement of "hematologic response" in patients with AL, however, is difficult because of the inherent low tumor burden. Often the changes small changes that constitute a "hematologic response" in AL patients are within the variability of the assays employed. Documenting a response in a cohort of patients who start with a median bone marrow plasmacytosis of 5-7% and median serum M-spike of 1 g/L is a challenge. More sensitive and reproducible methodology is required. There is one report from the United Kingdom in which the authors evaluated the role of changes of serum FLC, predominantly in a non-hematopoietic transplant setting. These authors found that the 5-year overall survival was more than doubled in patients achieving a 50% decline in serum FLC regardless of the therapeutic strategy. 11 Sanchorawala et al recently demonstrated that free light chain improvement correlated with complete hematologic response and were more readily detected early after treatment than were changes in immunofixation and bone marrow studies. 14 We hypothesized that FLC testing would make more patients evaluable for hematologic response and would also be more predictive for
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From outcome than immunofixation and bone marrow studies due to the inherent subjectivity in interpreting the former and the sampling variability in the latter. In the current study, we determined the relevance of FLC in our cohort of AL patients undergoing high dose chemotherapy with peripheral blood stem cell transplant (PBSCT).
Methods
The study population consisted of patients with documented AL 13 who underwent PBSCT and who had at least one immunoglobulin FLC measurement performed.
No patients with co-existent multiple myeloma (i.e. hypercalcemia, lytic bone disease, or hemoglobin less than 10) were included in the series. 12 Patients were considered evaluable for hematologic complete response if they did not meet the criteria before transplantation--that is, patients who were immunofixation negative and had fewer than 5% bone marrow plasma cells were considered inevaluable.
The prognostic effects of the size and the reduction of monoclonal FLC on survival were studied. These endpoints were computed using a Kaplan-Meier estimate; 16 curves were compared using the log-rank test. Survival was calculated from the Tables 1 and 2 These numbers are comparable to the respective survival rates (82% and 79%) of the entire population of amyloid patients (n=195) treated during the same time period , regardless of whether they had free light chain measurements available or not (data not shown).
Results

Patient Characteristics
Does the Baseline value of Immunoglobulin FLC Predict for Overall Survival?
The baseline value of involved immunoglobulin FLC was prognostic for overall Comparisons between the baseline characteristics of those patients with a pre-PBSCT FLC of less than or greater than the median value (152 mg/L) were made.
The only pre-transplant characteristics that differed between these two groups (Tables 1 and 2) were bone marrow plasmacytosis, number of organs involved, beta-2 microglobulin, serum cardiac troponin T, left ventricular interventricular septal thickness, and administration of reduced intensity conditioning. There was a weak correlation between cardiac troponin T levels and baseline immunoglobulin 
Does Post-transplantation Immunoglobulin FLC Predict for Response?
The changes of involved FLC and FLC ratio at day 100 and 1 year are shown in Figure 2a and Table 3 . The median percent of involved FLC remaining was 25% and 22% at 100 days and 1 year, respectively, while more than a quarter of patients had more than a 90% reduction in their FLC post-transplantation. Pre-transplant factors that predicted for normal FLC 3 months post-transplantation were: lower pre-transplant FLC (p=0.0006) and fewer number of organs involved (p=0.007).
No other factors predicted for achievement of a normal FLC post transplant.
Patients with normalized absolute FLC levels were most likely to have both hematologic and organ responses ( Table 4 ). The same was true for the ratio, with the exception that the ratio at 100 days did not predict for organ response. Of the 93 patients with day 100 free light chain values available, 87 were assessed for complete hematologic response; 2 were excluded because they did not have all appropriate studies done to document a complete hematologic response post transplant, and 4 were excluded because pre-transplant, neither immunofixation positive of the serum or urine was positive nor was there more than 5 percent bone For personal use only. on October 22, 2017. by guest www.bloodjournal.org From marrow plasmacytosis-i.e. they were 'inevaluable' by standard means. Forty-two (48%) had a complete hematologic response. Of the 74 patients with FLC measurement at 1 year, 35 (47%) achieved a complete hematologic response.
As shown in Table 4 , normalization of immunoglobulin FLC predicted for organ response. Of the 93 patients with FLC measurements at day 100, 45 patients (48%) have had organ response documented. Of the 78 patients with FLC measurements at 1 year, 39 (50%) had organ response documented. The FLC ratio did not predict for organ response.
Does Post-transplantation Immunoglobulin FLC Predict for Overall Survival?
The percent reduction of involved immunoglobulin FLC from baseline did not predict for overall survival, though achieving absolute low levels did. Overall survival was no different for those who had a 50% or 90% reduction at 3 months (Figures 2b and 2c) or at 1 year (data not shown). Even when the 5 patients with a normal baseline involved FLC were excluded from the analyses, the percent reduction relative to baseline was not predictive for overall survival (data not shown).
In contrast, survival was significantly better for those patients with the lowest immunoglobulin FLC post-transplantation ( at day 100 and at one year, respectively, and fewer than one quarter of patients had involved free light chain greater than 75 mg/L (Figure 3a) . As shown in Figures 3b and c, normalization of the FLC was associated with a significantly improved survival. Normalization of FLC by day 100 was associated with 0.13 hazard ratio of death. The ratio of involved to uninvolved FLC at 1 year approached significance as a predictor of survival; perhaps with longer follow up and more events, it will be statistically significant. Even dichotomizing patients into normal and abnormal ratios was not predictive. Free light chain response was a more powerful predictor of survival than complete hematologic response (Figure 4 ).
Discussion
We have made three novel observations regarding the utility of immunoglobulin FLC in patients with primary systemic amyloidosis undergoing PBSCT in our retrospective analysis. The first is that absolute levels of immunoglobulin FLC appear to be more relevant than the FLC ratio in this clinical setting. The second is that attainment of a low absolute level of involved immunoglobulin free light chain-rather than a percentage reduction-is the best immunoglobulin FLC predictor for hematologic response, organ response, and overall survival after PBSCT. The third is that the pre-transplantation immunoglobulin FLC has treatment groups the median percent of FLC remaining post therapy relative to baseline was 35, 43, and 38%, respectively, as compared to 22% in our transplant cohort. While 47% of their patients did not achieve a FLC reduction of 50% or more, only about 20% of our patients did not. Dose intensity can affect not only depth of response, but also durability of response. 6, 18 In addition, Lachmann et al reported that though a 50% reduction predicted for improved survival, a greater relative reduction did not further improve prognosis. This is in stark contrast to our findings. Hematologic response, using conventional means, has predicted for overall survival in patients with AL. [5] [6] [7] 13 Using the more sensitive and more quantitative FLC assay, we illustrate this same point. Whether one subscribes to the long-standing theory that the amyloid fibrils are the toxic species in patients with AL or the newer notion that the amyloidogenic light chains are actually the toxic species, 3 maximal eradication of monoclonal FLC would appear to be desirable.
Though decreases in FLC predicted for both organ response and complete hematologic response, immunoglobulin FLC was a better predictor of survival than only 6% of our patients had serum creatinine levels greater than 2 mg/dL.
In conclusion, our findings may have therapeutic implications in patients with AL undergoing PBSCT. Our data suggest that those patients who do not normalize their absolute FLC value post-transplant could be considered for further therapy.
Based on the results of our study, however, we do not yet recommend this as a routine practice since the risk to a patient is likely a function not only of absolute quantity of FLC, but also its quality-that is, its intrinsic amyloidogeneicity.
Ideally, our observations should be validated prospectively and by multiple centers.
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